EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Design, Synthesis, Anticancer Screening, and Mechanistic Study of Spiro-N-(4-sulfamoyl-phenyl)-1,3,4-thiadiazole-2-carboxamide Derivatives

Ahmed M El-Saghier iD, Hamada Hashem iD, Sherif A Maher, Souhaila S Enaili iD, Abdullah Alkhammash iD, Stefan Bräse iD, Hossameldin A Aziz

International Journal of Molecular Sciences · 20.01.2025 · 26 (2) · 863

DOI: 10.3390/ijms26020863 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.01.2025. Verfasst von Ahmed M El-Saghier und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Faculty of Science, Sohag University, Sohag 82524, Egypt. Hauptthemen laut MEDLINE: Antineoplastic Agents, Thiadiazoles, Carbonic Anhydrase Inhibitors, Drug Design. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The present study aims to create spiro-N-(4-sulfamoyl-phenyl)-1,3,4-thiadiazole-2-carboxamide derivatives with anticancer activities. The in vitro anticancer evaluation showed that only the novel spiro-acenaphthylene tethered-[1,3,4]-thiadiazole (compound 1) exhibited significant anticancer efficacy as a selective inhibitor of tumor-associated isoforms of carbonic anhydrase. Compound 1 demonstrated considerable efficacy against the renal RXF393, colon HT29, and melanoma LOX IMVI cancer cell lines, with IC50 values of 7.01 ± 0.39, 24.3 ± 1.29, and 9.55 ± 0.51 µM, respectively. In comparison, doxorubicin exhibited IC50 values of 13.54 ± 0.82, 13.50 ± 0.71, and 6.08 ± 0.32 µM for the corresponding cell lines. Importantly, compound 1 exhibited lower toxicity to the normal WI 38 cell line than doxorubicin, with IC50 values of 46.20 ± 2.59 and 18.13 ± 0.93 µM, respectively, indicating greater selectivity of the target compound compared to the standard anticancer agent doxorubicin. Also, mechanistic experiments demonstrated that compound 1 exhibits inhibitory activity against human carbonic anhydrase hCA IX and XII, with IC50 values of 0.477 ± 0.03 and 1.933 ± 0.11 μM, respectively, indicating enhanced selectivity for cancer-associated isoforms over cytosolic isoforms hCA I and II, with IC50 values of 7.353 ± 0.36 and 12.560 ± 0.74 μM, respectively. Cell cycle studies revealed that compound 1 caused G1 phase arrest in RXF393 cells, and apoptosis experiments verified a substantial induction of apoptosis with significant levels of early and late apoptosis, as well as necrosis (11.69%, 19.78%, and 3.66%, respectively), comparable to those induced by the conventional cytotoxic agent doxorubicin, at 9.91%, 23.37%, and 6.16%, respectively. Molecular docking experiments confirmed the strong binding affinity of compound 1 to the active sites of hCA IX and XII, highlighting significant interactions with zinc-binding groups and hydrophobic residues. These findings underscore the target compound’s potential as a viable anticancer agent via targeting CA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsThiadiazolesCarbonic Anhydrase InhibitorsDrug DesignHumansCell Line, TumorApoptosisMolecular Docking SimulationDrug Screening Assays, AntitumorCarbonic AnhydrasesStructure-Activity RelationshipCell ProliferationCarbonic Anhydrase IX

Stichwörter der Autor:innen

anticancercarbonic anhydrases inhibitormolecular dockingthiadiazole

Substanzen

Antineoplastic AgentsThiadiazolesCarbonic Anhydrase InhibitorsCarbonic AnhydrasesCarbonic Anhydrase IX

Autor:innen und Institutionen

  • Department of Chemistry, Faculty of Science, Sohag University, Sohag 82524, Egypt.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Sohag University, Sohag 82524, Egypt.
  • Department of Biochemistry, Faculty of Pharmacy, New Valley University, New Valley 72511, Egypt.
  • Department of Chemistry, Faculty of Science, University of Zawia, Az Zawiyah 16418, Libya.
  • Department of Pharmacology, College of Pharmacy, Shaqra University, Shaqra 11961, Saudi Arabia.
  • Institute for Biological and Chemical System, Karlsruhe Institute of Technology, 76131 Karlsruhe, Germany.

ORCID-Profile: Ahmed M El-Saghier, Hamada Hashem, Souhaila S Enaili, Abdullah Alkhammash, Stefan Bräse

Zitieren

APA

El-Saghier, A. M., Hashem, H., Maher, S. A., Enaili, S. S., Alkhammash, A., Bräse, S., & Aziz, H. A. (2025). Design, Synthesis, Anticancer Screening, and Mechanistic Study of Spiro-N-(4-sulfamoyl-phenyl)-1,3,4-thiadiazole-2-carboxamide Derivatives. International Journal of Molecular Sciences, 26(2), 863. https://doi.org/10.3390/ijms26020863

Vancouver

El-Saghier AM, Hashem H, Maher SA, Enaili SS, Alkhammash A, Bräse S, et al. Design, Synthesis, Anticancer Screening, and Mechanistic Study of Spiro-N-(4-sulfamoyl-phenyl)-1,3,4-thiadiazole-2-carboxamide Derivatives. International Journal of Molecular Sciences. 2025;26(2):863. doi:10.3390/ijms26020863

BibTeX
@article{ElSaghier2025,
  author = {El-Saghier, Ahmed M and Hashem, Hamada and Maher, Sherif A and Enaili, Souhaila S and Alkhammash, Abdullah and Bräse, Stefan and Aziz, Hossameldin A},
  title = {Design, Synthesis, Anticancer Screening, and Mechanistic Study of Spiro-N-(4-sulfamoyl-phenyl)-1,3,4-thiadiazole-2-carboxamide Derivatives},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {2},
  pages = {863},
  doi = {10.3390/ijms26020863}
}
Kostenlos starten →